Physician profile
Malvika Sachdev
NPI 1619009586
$558.24
in general payments reported to CMS, 2019-2025
15 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.24 · 2020: $22.56 · 2023: $67.91 · 2024: $80.41 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $128.06 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $79.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.99 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $45.87 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $36.62 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $31.38 | 2019-2024 | Ozempic, Rybelsus |
| Phadia US INC. | $25.83 | 2025 | Immunocap |
| Dexcom, INC. | $24.28 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.49 | 2025 | Xifaxan |
| Exact Sciences Corporation | $20.70 | 2023 | Cologuard Collection Kit |
| Alk-Abello, INC | $16.56 | 2023 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $15.94 | 2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $14.07 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.95 | 2019 | |
| Sanofi Pasteur INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malvika Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.